NEW YORK and SALT LAKE CITY, March 25, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will release its second quarter and first half fiscal year 2022 financial results on Thursday, March 31, 2022, before market open.
RNS Number : 9571F Renalytix PLC 25 March 2022 Renalytix plc ("Renalytix" or the "Company") Renalytix to Report Second Quarter and First Half Fiscal Year 2022 Financial Results on March 31 NEW YORK and SALT LAKE CITY , March 25, 2022 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today
myIntelX will be launching in conjunction with KidneyIntelX going live at Atrium Health, and will expand testing services across all Renalytix healthcare provider partners NEW YORK and SALT LAKE CITY, March 09, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the
RNS Number : 1092E Renalytix PLC 09 March 2022 Renalytix plc ("Renalytix" or the "Company") Renalytix Launches myIntelX, Providing National Physician Access to KidneyIntelX Testing Platform myIntelX will be launching in conjunction with KidneyIntelX going live at Atrium Health , and will
Data highlights strength of KidneyIntelX for clinical use in early-stage diabetic kidney disease patients beyond commonly used markers UACR and historical eGFR change over time NEW YORK and SALT LAKE CITY, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced
RNS Number : 6330C Renalytix PLC 24 February 2022 KidneyIntelX TM Clinical Results Presented at World Congress of Nephrology Demonstrate Improved Prediction of Kidney Function Over Standard of Care Data highlights strength of KidneyIntelX for clinical use in early-stage diabetic kidney
NEW YORK and SALT LAKE CITY, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (“Renalytix” or the “Company”) today announced the Company will be presenting at the upcoming virtual Cowen 42 nd Annual Health Care Conference. Renalytix’s management is scheduled to participate
NEW YORK and SALT LAKE CITY, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced its intention to appoint Timothy Scannell to its board of directors as an independent non-executive director. Mr. Scannell is a distinguished leader in healthcare innovation, who
RNS Number : 3488C Renalytix PLC 22 February 2022 Renalytix plc ("Renalytix" or the "Company") Renalytix to Present at Cowen 42 nd Annual Health Care Conference New York and SALT LAKE CITY , February 22, 2022 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) ("Renalytix" or the "Company") today
RNS Number : 3394C Renalytix PLC 22 February 2022 Renalytix plc ("Renalytix" or the "Company") Renalytix to Appoint Timothy Scannell to Board of Directors NEW YORK, NY and SALT LAKE CITY, UT February 22, 2022 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced its intention to